Home
MYGN
MYGN News

Latest Myriad Genetics Inc. (MYGN) News on February 22, 2025

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

GlobeNewswire

3 days ago

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Argus Research

4 days ago

MYGN: Raising target price to $12.00

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

GlobeNewswire

4 days ago

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

StockStory

5 days ago

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

MYGN Stock Might Rise on Collaboration With CancerCARE

Zacks

11 days ago

MYGN Stock Might Rise on Collaboration With CancerCARE

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

GlobeNewswire

16 days ago

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

MT Newswires

17 days ago

Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

GlobeNewswire

17 days ago

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

GlobeNewswire

17 days ago

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Argus Research

18 days ago

MYGN: What does Argus have to say about MYGN?

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

GlobeNewswire

24 days ago

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Argus Research

25 days ago

MYGN: What does Argus have to say about MYGN?

Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?

Insider Monkey

a month ago

Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?

MYGN Stock Gains Following the Launch of Know More Sooner

Zacks

a month ago

MYGN Stock Gains Following the Launch of Know More Sooner

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

GlobeNewswire

a month ago

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Argus Research

a month ago

MYGN: Rating decreased to a SELL

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

GlobeNewswire

a month ago

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

MT Newswires

a month ago

Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

GlobeNewswire

a month ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Argus Research

a month ago

MYGN: Lowering target price to $14.00

MYGN Stock Gains Following Collaboration With Hannah Storm

Zacks

a month ago

MYGN Stock Gains Following Collaboration With Hannah Storm

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

GlobeNewswire

a month ago

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a month ago

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a month ago

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

a month ago

Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

GlobeNewswire

a month ago

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

GlobeNewswire

2 months ago

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price

Simply Wall St.

2 months ago

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price

Argus Research

2 months ago

MYGN: Rating increased to a HOLD

MYGN Stock Might Gain From the New Recognition of RiskScore Study

Zacks

2 months ago

MYGN Stock Might Gain From the New Recognition of RiskScore Study

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

GlobeNewswire

2 months ago

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Argus Research

2 months ago

MYGN: Lowering target price to $11.00

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Zacks

2 months ago

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

MT Newswires

2 months ago

Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend

Argus Research

2 months ago

MYGN: Lowering target price to $12.00

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

GlobeNewswire

2 months ago

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

GlobeNewswire

2 months ago

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

GlobeNewswire

2 months ago

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Zacks

2 months ago

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

GlobeNewswire

2 months ago

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

MT Newswires

2 months ago

Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

GlobeNewswire

2 months ago

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

Argus Research

3 months ago

MYGN: What does Argus have to say about MYGN?

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Zacks

3 months ago

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

GlobeNewswire

3 months ago

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

GlobeNewswire

3 months ago

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

TipRanks

3 months ago

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

MT Newswires

3 months ago

Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Zacks

3 months ago

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

MT Newswires

3 months ago

Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

GlobeNewswire

3 months ago

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

Argus Research

3 months ago

MYGN: Lowering target price to $13.00

Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Zacks

3 months ago

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...

GuruFocus.com

3 months ago

Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...

Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

Zacks

3 months ago

Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Zacks

3 months ago

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Associated Press Finance

3 months ago

Myriad: Q3 Earnings Snapshot

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

GlobeNewswire

3 months ago

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Zacks

4 months ago

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Argus Research

4 months ago

MYGN: Lowering target price to $14.00

MT Newswires

4 months ago

Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

GlobeNewswire

4 months ago

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Myriad weakness due to UnitedHealth coverage update, says Stephens

TipRanks

4 months ago

Myriad weakness due to UnitedHealth coverage update, says Stephens

Morningstar Research

4 months ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

4 months ago

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Zacks

4 months ago

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Morningstar Research

4 months ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics Shares Fall Despite Partnership With jscreen

Zacks

4 months ago

Myriad Genetics Shares Fall Despite Partnership With jscreen

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

GlobeNewswire

4 months ago

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

GlobeNewswire

4 months ago

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week

Simply Wall St.

4 months ago

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests

Zacks

4 months ago

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests

Myriad signs five partnerships to study MRD testing in breast cancer

Clinical Trials Arena

4 months ago

Myriad signs five partnerships to study MRD testing in breast cancer

Argus Research

4 months ago

MYGN: What does Argus have to say about MYGN?

MT Newswires

4 months ago

Myriad Genetics Outlines Five Projects on Studying Breast Cancer Test

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

GlobeNewswire

4 months ago

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests

Medical Device Network

5 months ago

Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests

MT Newswires

5 months ago

Myriad Genetics, Ultima Genomics Collaborate to Explore UG 100 Sequencing Platform

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

GlobeNewswire

5 months ago

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

MT Newswires

5 months ago

Myriad Genetics Gets Third Patent for Molecular Residual Disease Assay

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

GlobeNewswire

5 months ago

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Zacks

5 months ago

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Morningstar Research

5 months ago

Analyst Report: Myriad Genetics, Inc.

MT Newswires

5 months ago

Myriad Genetics Has Many Opportunities for Growth, Needs Sustained Execution, Morgan Stanley Says

MT Newswires

5 months ago

Update: Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target

MT Newswires

5 months ago

Morgan Stanley Initiates Myriad Genetics at Equalweight

Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock

Zacks

5 months ago

Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

GlobeNewswire

5 months ago

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Should You Continue to Retain MYGN Stock in Your Portfolio?

Zacks

5 months ago

Should You Continue to Retain MYGN Stock in Your Portfolio?

Morningstar Research

5 months ago

Analyst Report: Myriad Genetics, Inc.

Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

5 months ago

Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

5 months ago

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)

MT Newswires

5 months ago

Myriad Genetics Insider Sold Shares Worth $400,800, According to a Recent SEC Filing

Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

5 months ago

Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)

MT Newswires

5 months ago

Myriad Genetics Insider Sold Shares Worth $270,520, According to a Recent SEC Filing

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Zacks

6 months ago

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Myriad Genetics to Host Investor Event on October 9, 2024

GlobeNewswire

6 months ago

Myriad Genetics to Host Investor Event on October 9, 2024

MT Newswires

6 months ago

Myriad Genetics Insider Sold Shares Worth $1,285,851, According to a Recent SEC Filing

Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

6 months ago

Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)

Share on Social Networks: